{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-004361","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.886787+00:00","generated_at":"2026-06-25T01:31:14.429394+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial","bullets":["Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.","Board plans to add capital markets experience; Iroquois has not recommended any candidate despite offer.","New executive compensation agreements tie cash and equity bonuses to achievement of corporate goals.","Company raised ~$90M in two capital raises and uplisted to Nasdaq; cash provides strategic advantage.","Company reiterates strategy will deliver higher shareholder value over time; rejects Iroquois' characterizations."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-004361","json":"https://secwatch.observer/filing/0001683168-22-004361.json","markdown":"https://secwatch.observer/filing/0001683168-22-004361.md","text":"https://secwatch.observer/filing/0001683168-22-004361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/0001683168-22-004361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:31:14.429394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}